

# Rodrigo Alonso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6280740/publications.pdf>

Version: 2024-02-01

32  
papers

2,242  
citations

304743

22  
h-index

395702

33  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1898  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | A resilient type of familial hypercholesterolaemia: caseâ€“control follow-up of genetically characterized older patients in the SAFEHEART cohort. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 795-801.                         | 1.8 | 12        |
| 2  | Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 427-434.   | 4.8 | 9         |
| 3  | Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study. <i>Atherosclerosis</i> , 2021, 317, 52-58.  | 0.8 | 16        |
| 4  | Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2021, 42, 2201-2211.  | 2.2 | 33        |
| 5  | Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. <i>Journal of Clinical Lipidology</i> , 2021, 15, 584-592.   | 1.5 | 13        |
| 6  | The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2414-2424.  | 5.3 | 44        |
| 7  | Dyslipidemia and aortic valve disease. <i>Current Opinion in Lipidology</i> , 2021, Publish Ahead of Print, 349-354.  | 2.7 | 11        |
| 8  | Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 828-834.                          | 0.6 | 3         |
| 9  | Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2508-2515.                            | 2.4 | 15        |
| 10 | &lt;p&gt;Lomitapide: a review of its clinical use, efficacy, and tolerability&lt;/p&gt;. <i>Core Evidence</i> , 2019, Volume 14, 19-30.   | 4.7 | 39        |
| 11 | Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 989-996.                           | 1.5 | 29        |
| 12 | Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 286, 40-45.                                 | 0.8 | 7         |
| 13 | Value of Measuring Lipoprotein(a) DuringÂCascade Testing for FamilialÂHypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1029-1039.   | 2.8 | 99        |
| 14 | Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients With Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 945-955. | 2.4 | 39        |
| 15 | Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 948-957. | 1.5 | 50        |
| 16 | Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?. <i>Current Opinion in Lipidology</i> , 2018, 29, 445-452.  | 2.7 | 22        |
| 17 | Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.                                  | 0.8 | 163       |
| 18 | Familial Hypercholesterolaemia Diagnosis and Management. <i>European Cardiology Review</i> , 2018, 13, 14.  | 2.2 | 32        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Plasma PCSK9 measurement by liquid chromatography–Tandem mass spectrometry and comparison with conventional ELISA. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1044-1045, 24-29. | 2.3 | 10        |
| 20 | Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 135, 2133-2144.  | 1.6 | 270       |
| 21 | Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. <i>Atherosclerosis</i> , 2017, 262, 8-13.  | 0.8 | 60        |
| 22 | Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. <i>Journal of Clinical Lipidology</i> , 2017, 11, 160-166.  | 1.5 | 23        |
| 23 | Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 953-961.  | 1.5 | 44        |
| 24 | Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2004-2010.  | 2.4 | 130       |
| 25 | Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1278-1285.  | 2.8 | 221       |
| 26 | Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 229-230.                  | 0.2 | 3         |
| 27 | Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. <i>Journal of Clinical Lipidology</i> , 2015, 9, 607-617.  | 1.5 | 40        |
| 28 | Lipoprotein(a) Levels in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1982-1989.  | 2.8 | 283       |
| 29 | Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.   | 1.7 | 316       |
| 30 | Detección de la hipercolesterolemia familiar: un modelo de medicina preventiva. <i>Revista Española De Cardiología</i> , 2014, 67, 685-688.  | 1.2 | 29        |
| 31 | Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). <i>Lipids in Health and Disease</i> , 2011, 10, 94.                                 | 3.0 | 121       |
| 32 | Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. <i>Clinical Biochemistry</i> , 2009, 42, 899-903.   | 1.9 | 48        |